The impact of the endothelin type A receptor on regional endothelin-1 turnover, in particular renal endothelin-1 release, in humans

Journal of Applied Physiology

Volumn 108, Issue 6, 2010, Pages 1625-1630

  Rullman, Eric ^a   Gustafsson, Thomas ^a   Ahlborg, Gunvor ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Blood flow; Endothelin converting enzyme 1; MRNA; Muscle; Pulmonary; Skeletal

Indexed keywords

ENDOTHELIN 1; ENDOTHELIN A RECEPTOR;

ADRENERGIC SYSTEM; ADULT; ARTICLE; HUMAN; KIDNEY; MALE; METABOLIC CLEARANCE RATE; METABOLISM; PHYSIOLOGY;

ADULT; ENDOTHELIN-1; HUMANS; KIDNEY; MALE; METABOLIC CLEARANCE RATE; RECEPTOR, ENDOTHELIN A; VASOMOTOR SYSTEM;

EID: 77953173416     PISSN: 87507587     EISSN: 15221601     Source Type: Journal    
DOI: 10.1152/japplphysiol.00881.2009     Document Type: Article

References (23)

1. Ahlborg G, Lindstrom J. Insulin sensitivity and big ET-1 conversion to ET-1 after ETA- or ETB-receptor blockade in humans. J Appl Physiol 93: 2112-2121, 2002.
2. Ahlborg G, Lundberg JM. Nitric oxide-endothelin-1 interaction in humans. J Appl Physiol 82: 1593-1600, 1997.
3. Ahlborg G, Ottosson-Seeberger A, Hemsen A, Lundberg JM. Big ET-1 infusion in man causes renal ET-1 release, renal and splanchnic vasoconstriction, and increased mean arterial blood pressure. Cardiovasc Res 28: 1559-1563, 1994.
4. Ahlborg G, Ottosson-Seeberger A, Hemsen A, Lundberg JM. Central and regional hemodynamic effects during infusion of Big endothelin-1 in healthy humans. J Appl Physiol 80: 1921-1927, 1996.
5. Ahlborg G, Weitzberg E, Lundberg JM. Circulating endothelin-1 reduces splanchnic and renal blood flow and splanchnic glucose production in humans. J Appl Physiol 79: 141-145, 1995.
6. Arai H, Hori S, Aramori I, Ohkubo H, Nakanishi S. Cloning and expression of a cDNA encoding an. endothelin receptor. Nature 348: 730-732, 1990. (Pubitemid 120015147)
7. Bohm F, Pernow J, Lindstrom J, Ahlborg G. ETA receptors mediate vasoconstriction, whereas ETB receptors clear endothelin-1 in the splanchnic and renal circulation of healthy men. Clin Sci (Lond) 104: 143-151, 2003.
8. Dagassan PH, Breu V, Clozel M, Kunzli A, Vogt P, Turina M, Kiowski W, Clozel JP. Up-regulation of endothelin-B receptors in atherosclerotic human coronary arteries. J Cardiovasc Pharmacol. 27: 147-153, 1996.
9. Davenport AP, Maguire JJ. Endothelin. In: Handbook of Experimental Pharmacology. Berlin: Springer, 2006, p. 295-329.
10. Fukuroda T, Fujikawa T, Ozaki S, Ishikawa K, Yano M, Nishikibe M. Clearance of circulating endothelin-1 by ETB receptors in rats. Biochem Biophys Res Commun 199: 1461-1465, 1994. (Pubitemid 124008917)
11. Goddard J, Johnston NR, Hand MF, Cumming AD, Rabelink TJ, Rankin AJ, Webb DJ. Endothelin-A receptor antagonism, reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure: A comparison of selective and combined endothelin receptor blockade. Circulation 109: 1186-1193, 2004.
12. Haynes WG, Webb DJ. Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet 344: 852-854, 1994.
13. Hemsen A, Ahlborg G, Ottosson-Seeberger A, Lundberg JM. Metabolism of Big endothelin-1 (1-38) and (22-38) in the human circulation in relation to production of endothelin-1 (1-21). Regul Pept 55: 287-297, 1995.
14. Lerman A, Edwards BS, Hallett JW, Heublein DM, Sandberg SM, Burnett JC Jr. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med 325: 997-1001, 1991.
15. Minamino T, Kurihara H, Takahashi M, Shimada K, Maemura K, Oda H, Ishikawa T, Uchiyama T, Tanzawa K, Yazaki Y. Endothelinconverting enzyme expression in the rat vascular injury model and human coronary atherosclerosis. Circulation 95: 221-230, 1997.
16. Ottosson-Seeberger A, Lundberg JM, Alvestrand A, Ahlborg G. Exogenous endothelin-1 causes peripheral insulin resistance in healthy humans. Acta Physiol Scand 161: 211-220, 1997. (Pubitemid 27445705)
17. Plumpton C, Ferro CJ, Haynes WG, Webb DJ, Davenport AP. The increase in human plasma immunoreactive endothelin but not big endothelin-1 or its C-terminal fragment induced by systemic administration of the endothelin antagonist TAK-044. Br J Pharmacol 119: 311-314, 1996.
18. Raoch V, Martinez-Miguel P, Arribas-Gomez I, Rodriguez-Puyol M, Rodriguez-Puyol D, Lopez-Ongil S. The peptidase inhibitor CGS-26303 increases endothelin converting enzyme-1 expression in endothelial cells through accumulation, of big endothelin-1. Br J Pharmacol 152: 313-322, 2007. (Pubitemid 47511258)
19. Sakurai T, Yanagisawa M, Takuwa Y, Miyazaki H, Kimura S, Goto K, Masaki T. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature 348: 732-735, 1990. (Pubitemid 120015148)
20. Seo B, Oemar BS, Siebenmann R, von Segesser L, Luscher TF. Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels. Circulation 89: 1203-1208, 1994. (Pubitemid 24076547)
21. Weitzberg E, Ahlborg G, Lundberg JM. Differences in vascular effects and removal of endothelin-1 in human lung, brain, and skeletal muscle. Clin Physiol 13: 653-662, 1993.
22. Weitzberg E, Ahlborg G, Lundberg JM. Long-lasting vasoconstriction and efficient regional extraction of endothelin-1 in human splanchnic and renal tissues. Biochem Biophys Res Commun 180: 1298-1303, 1991.
23. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332: 411-415, 1988.